Ratings Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Market Closed - Nyse 04:00:02 2024-05-03 pm EDT 5-day change 1st Jan Change
32.79 USD -0.82% Intraday chart for Perrigo Company plc +2.66% +1.90%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+1.90% 4.44B
B
+21.85% 546B
B
-4.77% 359B
C+
+16.97% 323B
B-
+5.69% 290B
C+
+13.68% 234B
B+
+3.65% 198B
B-
-11.12% 194B
A+
+8.08% 167B
C+
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PRGO Stock
  4. Ratings Perrigo Company plc